Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Briacell Therapeutics Corp. (OTC: BCTXF).

Full DD Report for BCTXF

You must become a subscriber to view this report.


Recent News from (OTC: BCTXF)

BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylve...
Source: GlobeNewswire
Date: April, 23 2018 06:30
BriaCell Provides Highlights of Scientific and Clinical Findings at AACR
BERKELEY, Calif. and VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it ha...
Source: GlobeNewswire
Date: April, 18 2018 09:30
Dr. Williams, BriaCell Therapeutics Corp.'s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT.V) (OTC:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s P...
Source: GlobeNewswire
Date: April, 11 2018 08:00
BriaCell to Present Encouraging Clinical Data at AACR 2018
BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it has been ...
Source: GlobeNewswire
Date: April, 10 2018 08:30
NetworkNewsBreaks - BriaCell Therapeutics Corp.'s (TSX-V: BCT) (OTCQB: BCTXF) Lead Product Candidate Highlighted in Frontiers in Immunology Publication
BriaCell Therapeutics (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, recently announced that a manuscript highlighting the company’s lead product candidate, Bria-IMT™, was published in Frontiers ...
Source: NetworkNewsWire
Date: April, 05 2018 12:30
BriaCell's Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptan...
Source: GlobeNewswire
Date: April, 03 2018 08:30
BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment With Leading U.S. Biotech Funds
BERKELEY, Calif. and VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the " Company ") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to ...
Source: GlobeNewswire
Date: March, 27 2018 08:30
BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Raising Investments, Awareness and Enrollment in Clinical Trials
Using a proprietary technology platform in development of immunotherapy treatments to fight cancer Company recently announced proposed investment by leading biotech funds and concurrent non-brokered financing for combined gross proceeds of up to $4.8 million Using social media to raise ...
Source: NetworkNewsWire
Date: March, 26 2018 09:30
NetworkNewsBreaks - BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Details Proposed Financing Deals Valued at Up to $4.8M
Immuno-oncology focused biotechnology company BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) recently announced plans to enter into a securities purchase agreement of convertible notes with a leading group of biotech-focused institutional and family office funds for an investment of $...
Source: NetworkNewsWire
Date: March, 16 2018 09:30
BriaCell Appoints Top Social Media Marketing Analyst
BERKELEY, Calif. and VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it has engaged Aka...
Source: GlobeNewswire
Date: March, 14 2018 12:20

 


About Briacell Therapeutics Corp. (OTC: BCTXF)

Logo for Briacell Therapeutics Corp. (OTC: BCTXF)

BriaCell is an immuno oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off the shelf personalized approach to immunotherapy. The company is currently conducting a Phase IIa clinical trial for its lead product candidate, Bria IMT, in patients with advanced breast cancer. This trial is listed in ClinicalTrials.gov as NCT . The trial is being conducted along with the co development of BriaDX, the Company s companion diagnostic test. Additionally, there is an FDA approved roll over combination study of Bria IMT with pembrolizumab Keytruda manufactured by Merck amp Co., Inc. or ipilimumab Yervoy manufactured by Bristol Myers Squibb Company for patients with advanced breast cancer previously treated with Bria IMT. The roll over trial is listed in ClinicalTrials.gov as NCT . Additionally, BriaCell is developing Bria OTS, the first off the shelf personalized treatment for advanced stage Breast Cancer. Finally, BriaCell s small molecule program consists of novel, selective protein kinase C delta PKCo inhibitors. PKCo inhibitors have shown activity in a number of pre clinical models of RAS genes transformed cancers including breast, pancreatic, non small cell lung cancer, melanoma and neuroendocrine tumors such as carcinoid tumors . This technology also has applications for treating patients with fibrotic diseases

 

 

 

Current Management

  • William V. Williams, MD / CEO
  • Gadi Levin / CFO
    • Mr. Gadi Levin, age , Chief Financial Officer. Mr. Levin has over years of experience working with public US, Canadian and multijurisdictional public companies. Mr. Levin currently serves as Chief Financial Officer of Briacell Therapeutics Corp OTCQB: BCTXF, TSXV: BRIA.V and Adira Energy Limited OTCMKTS:ADENF, TSX.V: ADL.V . Previously, Mr. Levin served as Chief Financial Officer of DarioHeath Corp NASDAQ: DRIO , a mHealth company operating in the field diabetes management. Mr. Levin also served as the Vice President of Finance and Chief Financial Officer for two Israeli investment firms specializing in private equity, hedge funds and real estate. Mr. Levin began his CPA career at the accounting firm, Arthur Andersen, where he worked for nine years, specializing in U.S. listed companies involved in IPO s working with US GAAP and IFRS. Mr. Levin has a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a post graduate diploma in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.
  • Farrah Dean / VP, Corp. Dev.
  • Dr. Saeid Babaei / Chairman
  • William V. Williams, MD /
  • Martin Schmieg /
  • Rahoul Sharan /
  • Dr. Charles Wiseman /

Current Share Structure

  • Market Cap: $9,586,500 - 03/16/2018
  • Issue and Outstanding: 91,300,000 - 12/27/2016
  • Float: 72,270,000 - 12/27/2016

 


Recent Filings from (OTC: BCTXF)

Interim Financial Report - Condensed Interim Consolidated Financial Statements For the Three Months Ended October 31, 2017
Filing Type: Interim Financial Report - Condensed Interim Consolidated Financial Statements For the Three Months Filing Source: OTC Markets
Filing Date: January, 02 2018
Interim Financial Report - 52-109FV2 - Certification of interim filings - CFO (E)
Filing Type: Interim Financial Report - 52-109FV2 - Certification of interim filings - CFO (E)Filing Source: OTC Markets
Filing Date: January, 02 2018
Interim Financial Report - 52-109FV2 - Certification of interim filings - CEO (E)
Filing Type: Interim Financial Report - 52-109FV2 - Certification of interim filings - CEO (E)Filing Source: OTC Markets
Filing Date: January, 02 2018
Supplemental Information - 52-109FV1 - Certification of annual filings - CEO (E)
Filing Type: Supplemental Information - 52-109FV1 - Certification of annual filings - CEO (E)Filing Source: OTC Markets
Filing Date: November, 24 2017
Supplemental Information - Form 52-109FV1, Certification of Annual Filings (CFO)
Filing Type: Supplemental Information - Form 52-109FV1, Certification of Annual Filings (CFO)Filing Source: OTC Markets
Filing Date: November, 24 2017
Management Discussion and Analysis - Managements Discussion and Analysis For The Year Ended July 31, 2017
Filing Type: Management Discussion and Analysis - Managements Discussion and Analysis For The Year Ended July 31,Filing Source: OTC Markets
Filing Date: November, 24 2017
Annual Report - Consolidated Financial Statements For the Years Ended July 31, 2017 and 2016
Filing Type: Annual Report - Consolidated Financial Statements For the Years Ended July 31, 2017 and 2016Filing Source: OTC Markets
Filing Date: November, 24 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: August, 09 2017
Interim Financial Report - Form 52-109FV2, Certification of Interim Filings (CFO)
Filing Type: Interim Financial Report - Form 52-109FV2, Certification of Interim Filings (CFO)Filing Source: OTC Markets
Filing Date: June, 30 2017
Interim Financial Report - Form 52-109FV2, Certification of Interim Filings (CEO)
Filing Type: Interim Financial Report - Form 52-109FV2, Certification of Interim Filings (CEO)Filing Source: OTC Markets
Filing Date: June, 30 2017

 

 


Daily Technical Chart for (OTC: BCTXF)

Daily Technical Chart for (OTC: BCTXF)


Stay tuned for daily updates and more on (OTC: BCTXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BCTXF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCTXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BCTXF and does not buy, sell, or trade any shares of BCTXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/